{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-005732","form_type":"8-K","ticker":"LMAT","cik":"0001158895","company_name":"LEMAITRE VASCULAR INC","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.527687+00:00","generated_at":"2026-06-05T10:42:58.852385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LeMaitre Q4 sales $48.9M (+19%), EPS $0.38 (+49%); declares $0.16 dividend, $50M buyback","bullets":["Q4 2023 sales $48.9M (+19% YoY), net income $8.5M (+50%), EPS $0.38 (+49%).","Gross margin 68.1% (+450 bps) driven by ASP increases and manufacturing efficiencies.","Segment highlights: allografts +52%, bovine patches +18%, EMEA sales +21%.","Full year 2024 guidance: sales $209.7-$214.3M (midpoint +10%), EPS $1.60-$1.71.","Board declares $0.16/share dividend (payable Mar 28) and authorizes $50M share buyback."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-005732","json":"https://secwatch.observer/filing/0001437749-24-005732.json","markdown":"https://secwatch.observer/filing/0001437749-24-005732.md","text":"https://secwatch.observer/filing/0001437749-24-005732.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158895/000143774924005732/0001437749-24-005732-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158895/000143774924005732/lmat20240227_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T10:42:58.852385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"604deb2c62f3cd1f4424c74b108ce89bdbbf1de6","claim":"LEMAITRE VASCULAR INC reported the quarter ended December 31, 2023 results: revenue $48.9mm, net income $8.5mm, EPS $0.38. Guidance initiated.","evidence_excerpt":"of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results ● Sales $48.9mm, +19% (+14% organic) vs. Q4 2022 ● Gross margin 68.1%, +450 bps ● Op. income $10.2mm, +46% ● Op. margin 21% ● Net income $8.5mm, +50% ● Earnings per diluted share $0.38, +49% ●","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1158895/000143774924005732/0001437749-24-005732-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$48.9mm"},{"label":"Net income","value":"$8.5mm"},{"label":"EPS","value":"$0.38"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}